Division of GI/Hepatology, University of Virginia, 1335 Lee Street, Box 800708, Charlottesville, VA 22908-0708, USA.
Division of GI/Hepatology, University of Virginia, 1335 Lee Street, Box 800708, Charlottesville, VA 22908-0708, USA.
Clin Liver Dis. 2025 Feb;29(1):135-147. doi: 10.1016/j.cld.2024.08.004. Epub 2024 Sep 20.
Management of cirrhosis sequelae is critical in providing the most options for patients with hepatocellular carcinoma (HCC). Compensated liver disease is the ideal state for HCC patients who may require resection, locoregional therapies, or liver transplantation. Portal hypertension complications, suboptimal nutrition, and frailty are common barriers to various HCC treatments. For patients with advanced HCC, systemic therapies are altering the approach to multifocal, unresectable HCC, but similar barriers exist related to managing cirrhosis complications. Frequently, managing the underlying liver disease etiology is a key component to enabling HCC treatment.
肝硬化并发症的管理对于为肝细胞癌 (HCC) 患者提供最多选择至关重要。代偿性肝病是 HCC 患者可能需要接受肝切除术、局部区域治疗或肝移植的理想状态。门脉高压并发症、营养状况不佳和虚弱是各种 HCC 治疗的常见障碍。对于晚期 HCC 患者，系统治疗正在改变多灶性、不可切除 HCC 的治疗方法，但与管理肝硬化并发症相关的类似障碍仍然存在。通常，管理潜在的肝病病因是实现 HCC 治疗的关键组成部分。
